Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Conditions
Brief summary
This randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that has come back. Drugs used in chemotherapy, such as eribulin mesylate and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Detailed description
PRIMARY OBJECTIVES: I. To demonstrate that patient-reported Patient-Report Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data will be able to detect differences in symptoms between participants treated witheribulin mesylate (eribulin) and standard weekly paclitaxel at 12 weeks. II. To validate rs7349683 in EPHA5 as a predictor of peripheral neuropathy from treatment with a microtubule targeting agent (i.e., eribulin or paclitaxel). SECONDARY OBJECTIVES: I. To compare overall survival, progression free survival (PFS), objective response rate (ORR), duration of response (DOR), and time to treatment failure (TTF) in patients receiving eribulin versus standard weekly paclitaxel. II. To compare the 12 month rate of disease progression in patients receiving eribulin versus standard weekly paclitaxel. III. To evaluate the clinical value and feasibility of collecting patient-reported symptom toxicity information via the Patient-Report Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). IV. To further validate the PRO-CTCAE sensory neuropathy items. V. To compare patient reported neurotoxicity between arms using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Chemotherapy-Induced Peripheral Neuropathy 20 (CIPN20) instrument. VI. To assess the toxicities in patients receiving eribulin versus standard weekly paclitaxel. CORRELATIVE OBJECTIVES: I. To compare new metastasis free survival in patients receiving eribulin versus standard weekly paclitaxel. II. To explore the relationship between common single nucleotide polymorphisms in FGD4, FZD3, and VAC14 as predictors of peripheral neuropathy from treatment with a microtubule targeting agent (i.e., eribulin or paclitaxel). III. To evaluate circulating nucleosomes and the apoptosis associated M30 neo-epitope as potential biomarkers associated with clinical benefit from treatment with eribulin specifically or the microtubule dynamics inhibitors in general. VI. To evaluate tubulin isotype expression, mutations, and signaling pathway modifications in tumor tissue as potential biomarkers associated with clinical benefit from treatment with eribulin specifically or the microtubule dynamics inhibitors in general. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive eribulin mesylate intravenously (IV) over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 12 weeks.
Interventions
OTHERQuality-of-Life Assessment
Ancillary studies
DRUGEribulin Mesylate
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
DRUGPaclitaxel
Given IV
Sponsors
National Cancer Institute (NCI)
Academic and Community Cancer Research United
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Informed consent document signed and dated by patient * Histologic confirmation of invasive adenocarcinoma originating in the breast * Stage IV disease or stage IIIC disease (using the 7th edition American Joint Committee on Cancer \[AJCC\] criteria) not amenable to local therapy * Clinical or radiographic evidence of disease progression * Documentation of HER2 negative breast cancer at the time of protocol registration; (Note: HER2 negativity is defined as 0 or 1+ by immunohistochemistry OR nonamplified or equivocal by fluorescence in situ hybridization \[FISH\]; status may be defined on the basis of historic results on the breast primary or a metastatic site, whichever is most recent; repeat biopsies are not required for participation in this protocol) * Known hormone receptor status at the time of protocol registration; (Note: estrogen receptor \[ER\] and/or progesterone receptor \[PgR\] status are considered positive with a cut-off of \>= 1% invasive tumor cells; status may be defined on the basis of historic results on the breast primary or a metastatic site, whichever is most recent; repeat biopsies are not required for participation in this protocol) * Patients must demonstrate resolution of all toxicities related to prior chemotherapy, endocrine therapy, targeted therapy, or biologic therapy to grade =\< 1, including peripheral neuropathy, with the exception of alopecia (any grade permissible) * No more than one prior chemotherapy regimen for advanced or metastatic breast cancer is allowed; prior chemotherapy for metastatic disease must have been completed \>= 14 days prior to randomization * Any single agent therapy, and any combination of cytotoxic, endocrine, biological targeted agents, and/or humanized antibodies, scheduled to be administered as a preplanned treatment, given concomitantly, sequentially or both, is considered one regimen * Planned neoadjuvant chemotherapy and postoperative adjuvant chemotherapy is considered one regimen * If the dosing of one or more of the chemotherapy components of a regimen must be reduced for toxicity, the modified version of the original regimen is not considered a new regimen * If one or more of the chemotherapy components of a regimen must be omitted for toxicity, the modified version of the original regimen is not considered a new regimen * If one of the chemotherapy components of a regimen must be replaced with another similar drug of the same therapeutic class, the modified version of the original regimen is not considered a new regimen; however, if a new component, dissimilar to any of the original components, is added to the regimen, the modified version is considered a new regimen * If chemotherapy is interrupted for surgery or radiotherapy and then continues with an unchanged schedule and components, treatment is considered as one regimen despite the interruption * Prior treatment may include a taxane as per the following criteria: * Prior taxane (including paclitaxel) in the adjuvant or neoadjuvant setting is allowed, provided that the interval between the completion of (neo)adjuvant therapy and disease recurrence is \> 12 months * Prior taxane in the metastatic setting is allowed, provided that the agent administered in the metastatic setting was not standard paclitaxel * Any number of prior endocrine therapies is allowed and must be discontinued prior to randomization * Any number of biologic therapies (e.g., bevacizumab) or immunotherapies is allowed in the absence of co-administered chemotherapy and must have been completed \>= 28 days prior to randomization * Prior treatment with an investigational agent is allowed but must have been completed \>= 28 days prior to randomization with resolution of all treatment-related toxicities to grade =\< 1. * Minor surgical procedures must be completed \>= 7 days prior to randomization with documentation of adequate recovery from associated complications to grade =\< 1; these include (but are not limited to) laparoscopy, thoracoscopy, bronchoscopy, mediastinoscopy, endoscopic ultrasonography, skin biopsy, percutaneous needle biopsy, and routine dental procedures; as a precautionary measure, it is recommended, but not strictly required, that placement of a central venous access device, thoracentesis, or paracentesis be done 7 days before the initiation of protocol directed chemotherapy with documentation of adequate recovery from associated complications to grade =\< 1 * Major surgical procedures and open biopsies must be completed \>= 28 days prior to randomization with documentation of adequate recovery from associated complications to grade =\< 1 * Prior radiotherapy must be completed \>= 14 days prior to randomization with documentation of adequate recovery from associated toxicities to grade =\< 1 * Treatment with bisphosphonates or denosumab is allowed and recommended per the standard of care * Therapeutic anticoagulation is allowed for patients on a stable dose of warfarin or low molecular weight heparin * Measurable disease is defined as at least one lesion that can be accurately measured with the longest diameter as \>= 1.0 cm by computed tomography (CT) scan or \>= 1.0 cm with calipers by clinical examination; the exceptions to these criteria are pathologic lymph nodes, which must be \>= 1.5 cm in the short axis when assessed by CT scans with slice thickness =\< 0.5 cm * Non-measurable lesions include the following: small lesions (longest diameter \< 1.0 cm for all lesions other than pathologic lymph nodes, which are \>= 1.0 cm and \< 1.5 cm in the short axis), bone metastases, pleural effusions, pericardial effusions, ascites, inflammatory breast disease, leptomeningeal disease, lymphangitis pulmonis, lymphangitis cutis, and abdominal masses not followed by CT or magnetic resonance imaging (MRI) * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Life expectancy of \> 12 weeks * Patients with a history of resected brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including =\< 28 days of study registration * Patients who receive stereotactic radiosurgery or whole brain radiation for brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including =\< 28 days of study registration * Obtained =\< 7 days prior to registration: Absolute neutrophil count \>= 1500/uL * Obtained =\< 7 days prior to registration: Platelet count \>= 100,000/uL * Obtained =\< 7 days prior to registration: Hemoglobin \>= 9 g/dL * Obtained =\< 7 days prior to registration: Total bilirubin =\< 1.5 times the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert?s syndrome * Obtained =\< 7 days prior to registration: Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferases \[AST\]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 3 x ULN except in the case of liver metastases, where =\< 5 x ULN is allowed * Obtained =\< 7 days prior to registration: Creatinine =\< 2.0 mg/dL or creatinine clearance \> 50 mL/min * Obtained =\< 7 days prior to registration: Corrected QT (QTc) interval =\< 500 msec on the baseline electrocardiogram * Negative pregnancy test done =\< 72 hours prior to registration for women of childbearing potential only; Note: all female subjects will be considered to be of child-bearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically (i.e., bilateral tubal ligation \>= 1 menstrual cycle prior to randomization, or have undergone a hysterectomy and/or bilateral oophorectomy) * Female subjects of child-bearing potential must agree to use highly effective contraception during the study treatment and for 3 months after the final dose of study treatment; female subjects exempt from this requirement are subjects who practice total abstinence; if currently abstinent, the subject must agree to use a double barrier method of contraception (i.e., condom and occlusive cap \[diaphragm or cervical/vault caps\]) with spermicide or until they are established on highly effective contraception for at least one menstrual cycle if they become sexually active during the study treatment and for 3 months after the final dose of study treatment * Highly effective contraception includes: * Placement of intrauterine device or system * Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault cap) with spermicide * Vasectomized partner with confirmed azoospermia * Male subjects and their female partner who are of child-bearing potential (as defined above), and are not practicing total abstinence, must agree to use highly effective contraception during study treatment and for 3 months after the final dose of study treatment; if currently abstinent, the subject must agree to use a double barrier method of contraception if they become sexually active, or until they are established on highly effective contraception as described above * Ability to complete questionnaire(s) independently or with assistance * Willingness to provide blood and tissue samples for correlative research purposes; (Note: these tissue samples are from archived tissue, if available; new biopsies are not required) * Ability to comprehend and respond to questions using a telephone keypad
Exclusion criteria
* Prior malignancy, other than carcinoma in situ of the cervix and non-melanoma skin cancers, unless the prior malignancy was diagnosed and definitively treated \>= 5 years previously, there is no subsequent evidence of recurrence, and the patient is considered by a physician to be at \< 30% risk of relapse * Any of the following: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception * Presence of a serious nonhealing wound, ulcer, or bone fracture * History of Common Terminology Criteria for Adverse Events (CTCAE) grade \>= 3 hypersensitivity to paclitaxel or Cremophor EL * Pre-existing peripheral neuropathy grade ?= 2 at registration * Significant cardiovascular impairment (e.g., New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia) * Subjects with known positive human immunodeficiency virus (HIV) status * History of stroke or transient ischemic attack =\< 6 months prior to registration * History of uncontrolled seizures; (Note: patients are eligible for the study if the seizures are well controlled with standard medications) * Severe or uncontrolled intercurrent illness/infection * Concurrent administration of any other investigational agent considered to have potential efficacy in the treatment of breast cancer * Prior exposure to eribulin mesylate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change in Patient Reported PRO-CTCAE | 12 weeks | To demonstrate that patient-reported PRO-CTCAE data will be able to detect differences in symptoms between participants treated with eribulin and standard weekly paclitaxel at 12 weeks we will compare the mean change of overall Pro-CTCAE score by treatment arm. The overall Pro-CTCAE score is a normalized score scaled from 20 questions, each with a possible 1-5 patient selection, creating an overall score (0-100) where 0 represents the best outcome and 100 represents the worst possible outcome. The mean change from baseline to week 12 is reported. |
| Cumulative Dose Level Triggering a Grade 2 or Higher Neuropathy Event. | 6 months | To validate rs7349683 in EPHA5 as a predictor of peripheral neuropathy from treatment with a microtubule targeting agent (i.e., eribulin or paclitaxel) over the first 6 months of treatment we will compare the median cumulative dose level triggering a grade 2 or higher neuropathy event. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | 81 months | The primary analysis will use the stratified log-rank tests, as described for overall survival. As a secondary analysis we will use a multivariable Cox proportional hazard model to estimate adjusted hazard ratios for eribulin mesylate over standard weekly paclitaxel, study stratification factors, and covariates for known prognostic factors, including disease free interval and visceral versus non-visceral metastases. Survival functions will be summarized using the Kaplan-Meier method according to treatment group. |
| Objective Tumor Response Rate | 64 months | Objective tumor response rate is assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 |
| Duration of Response | 75 months | Will be summarized using the Kaplan-Meier method. Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals. Duration of response is the time between a tumor response and progression. |
| Time to Treatment Failure | 64 months | Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals. |
| Incidence of Treatment Related Adverse Events | 64 months | The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting. Each CTCAE term in the current version is a unique representation of a specific event used for medical documentation and scientific analysis and is a single MedDRA Lowest Level Term (LLT). Events determined to be possibly or probably attributed to a medical treatment suggest there is evidence to indicate a causal relationship between the drug and the adverse event. The number of patients that experienced an AE, of any grade, determined to be possibly or probably attributed to a medical treatment will be reported by arm. |
| Time to New Metastasis | 81 months | Will be summarized using the Kaplan-Meier method. Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals. |
| Progression Free Survival Assessed by RECIST 1.1 Criteria | 80 months | Will be summarized using the Kaplan-Meier method. Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals. Progression free survival time is the time from date of randomization to the date of first progression or death. |
| Validation of PRO-CTCAE Sensory Neuropathy Item | At baseline, 12, and 24 weeks | The PRO-CTCAE sensory neuropathy items will be further validated by computing Pearson correlations between each item, severity and interference, and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Chemotherapy-Induced Peripheral Neuropathy 20 (CIPN20 )sensory scale score at baseline, 12 and 24 weeks. |
| Patients With Reported Neurotoxicity | 24 weeks | Additional analyses will include the previously described analysis conducted over the first 24 weeks; a comparison of the incidence of patient-reported maximum score \>= 3 between arms through 12 and 24 weeks using chi-squared testing for each item; and a comparison of the time to patient-reported score \>= 3 between arms using Kaplan-Meier and log-rank analyses. Further, these three endpoints will be compared between patient- and clinician-report overall and within arms using appropriate paired analyses. |
Other
| Measure | Time frame | Description |
|---|---|---|
| New Metastasis Free Survival | Up to 5 years | Will be summarized using the Kaplan-Meier method according to treatment group. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm A (Eribulin) Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. | 101 |
| Arm B (Paclitaxel) Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | 100 |
| Total | 201 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 0 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 3 |
Baseline characteristics
| Characteristic | Arm B (Paclitaxel) | Total | Arm A (Eribulin) |
|---|---|---|---|
| Age, Continuous | 62 years | 62 years | 62 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 7 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 95 Participants | 190 Participants | 95 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 4 Participants | 3 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 20 Participants | 32 Participants | 12 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 3 Participants | 1 Participants |
| Race (NIH/OMB) White | 76 Participants | 161 Participants | 85 Participants |
| Sex: Female, Male Female | 100 Participants | 199 Participants | 99 Participants |
| Sex: Female, Male Male | 0 Participants | 2 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 80 / 101 | 79 / 100 |
| other Total, other adverse events | 99 / 101 | 95 / 100 |
| serious Total, serious adverse events | 30 / 101 | 30 / 100 |
Outcome results
Primary
Cumulative Dose Level Triggering a Grade 2 or Higher Neuropathy Event.
To validate rs7349683 in EPHA5 as a predictor of peripheral neuropathy from treatment with a microtubule targeting agent (i.e., eribulin or paclitaxel) over the first 6 months of treatment we will compare the median cumulative dose level triggering a grade 2 or higher neuropathy event.
Time frame: 6 months
Population: All treated patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Eribulin) | Cumulative Dose Level Triggering a Grade 2 or Higher Neuropathy Event. | 39.25 mg/m^2 |
| Arm B (Paclitaxel) | Cumulative Dose Level Triggering a Grade 2 or Higher Neuropathy Event. | 3950 mg/m^2 |
Primary
Mean Change in Patient Reported PRO-CTCAE
To demonstrate that patient-reported PRO-CTCAE data will be able to detect differences in symptoms between participants treated with eribulin and standard weekly paclitaxel at 12 weeks we will compare the mean change of overall Pro-CTCAE score by treatment arm. The overall Pro-CTCAE score is a normalized score scaled from 20 questions, each with a possible 1-5 patient selection, creating an overall score (0-100) where 0 represents the best outcome and 100 represents the worst possible outcome. The mean change from baseline to week 12 is reported.
Time frame: 12 weeks
Population: Treated patients that completed baseline and week 12 patient reported PRO-CTCAE packets.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm A (Eribulin) | Mean Change in Patient Reported PRO-CTCAE | 3.72 score on a scale | Standard Deviation 0.57 |
| Arm B (Paclitaxel) | Mean Change in Patient Reported PRO-CTCAE | 3.77 score on a scale | Standard Deviation 0.61 |
Secondary
Duration of Response
Will be summarized using the Kaplan-Meier method. Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals. Duration of response is the time between a tumor response and progression.
Time frame: 75 months
Population: All patients that achieved a response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Eribulin) | Duration of Response | 13.7 Months |
| Arm B (Paclitaxel) | Duration of Response | 14.1 Months |
Secondary
Incidence of Treatment Related Adverse Events
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting. Each CTCAE term in the current version is a unique representation of a specific event used for medical documentation and scientific analysis and is a single MedDRA Lowest Level Term (LLT). Events determined to be possibly or probably attributed to a medical treatment suggest there is evidence to indicate a causal relationship between the drug and the adverse event. The number of patients that experienced an AE, of any grade, determined to be possibly or probably attributed to a medical treatment will be reported by arm.
Time frame: 64 months
Population: All enrolled patients
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A (Eribulin) | Incidence of Treatment Related Adverse Events | 94 Participants |
| Arm B (Paclitaxel) | Incidence of Treatment Related Adverse Events | 90 Participants |
Secondary
Objective Tumor Response Rate
Objective tumor response rate is assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Time frame: 64 months
Population: All treated patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A (Eribulin) | Objective Tumor Response Rate | 0.14 proportion of participants |
| Arm B (Paclitaxel) | Objective Tumor Response Rate | 0.21 proportion of participants |
Secondary
Overall Survival (OS)
The primary analysis will use the stratified log-rank tests, as described for overall survival. As a secondary analysis we will use a multivariable Cox proportional hazard model to estimate adjusted hazard ratios for eribulin mesylate over standard weekly paclitaxel, study stratification factors, and covariates for known prognostic factors, including disease free interval and visceral versus non-visceral metastases. Survival functions will be summarized using the Kaplan-Meier method according to treatment group.
Time frame: 81 months
Population: All enrolled patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Eribulin) | Overall Survival (OS) | 18.1 months |
| Arm B (Paclitaxel) | Overall Survival (OS) | 16.4 months |
p-value: 0.5623Log Rank
Secondary
Patients With Reported Neurotoxicity
Additional analyses will include the previously described analysis conducted over the first 24 weeks; a comparison of the incidence of patient-reported maximum score \>= 3 between arms through 12 and 24 weeks using chi-squared testing for each item; and a comparison of the time to patient-reported score \>= 3 between arms using Kaplan-Meier and log-rank analyses. Further, these three endpoints will be compared between patient- and clinician-report overall and within arms using appropriate paired analyses.
Time frame: 24 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A (Eribulin) | Patients With Reported Neurotoxicity | 26 Participants |
| Arm B (Paclitaxel) | Patients With Reported Neurotoxicity | 31 Participants |
Secondary
Progression Free Survival Assessed by RECIST 1.1 Criteria
Will be summarized using the Kaplan-Meier method. Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals. Progression free survival time is the time from date of randomization to the date of first progression or death.
Time frame: 80 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Eribulin) | Progression Free Survival Assessed by RECIST 1.1 Criteria | 5.7 Months |
| Arm B (Paclitaxel) | Progression Free Survival Assessed by RECIST 1.1 Criteria | 5.9 Months |
p-value: 0.5968Log Rank
Secondary
Time to New Metastasis
Will be summarized using the Kaplan-Meier method. Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals.
Time frame: 81 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Eribulin) | Time to New Metastasis | 8.2 Months |
| Arm B (Paclitaxel) | Time to New Metastasis | 8.7 Months |
p-value: 0.984Log Rank
Secondary
Time to Treatment Failure
Will use a two-sided type I alpha of 0.05, and point estimates will be reported with 95% confidence intervals.
Time frame: 64 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Eribulin) | Time to Treatment Failure | 5.3 Months |
| Arm B (Paclitaxel) | Time to Treatment Failure | 4.9 Months |
Secondary
Validation of PRO-CTCAE Sensory Neuropathy Item
The PRO-CTCAE sensory neuropathy items will be further validated by computing Pearson correlations between each item, severity and interference, and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Chemotherapy-Induced Peripheral Neuropathy 20 (CIPN20 )sensory scale score at baseline, 12 and 24 weeks.
Time frame: At baseline, 12, and 24 weeks
Population: This analysis was pre-specified in the Statistical Analysis Plan to be conducted overall and not separately for each of the arms. Only patients that fully filled out and submitted their PRO-CTCAE and EORTC QLQ-CIPN20 packets are included in this analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A (Eribulin) | Validation of PRO-CTCAE Sensory Neuropathy Item | Week 12 - interference | 0.51 Pearson correlation |
| Arm A (Eribulin) | Validation of PRO-CTCAE Sensory Neuropathy Item | Baseline - Severity | 0.72 Pearson correlation |
| Arm A (Eribulin) | Validation of PRO-CTCAE Sensory Neuropathy Item | Baseline - interference | 0.67 Pearson correlation |
| Arm A (Eribulin) | Validation of PRO-CTCAE Sensory Neuropathy Item | Week 12 - severity | 0.71 Pearson correlation |
| Arm A (Eribulin) | Validation of PRO-CTCAE Sensory Neuropathy Item | Week 24 - severity | 0.79 Pearson correlation |
| Arm A (Eribulin) | Validation of PRO-CTCAE Sensory Neuropathy Item | Week 24 - interference | 0.85 Pearson correlation |
Other Pre-specified
New Metastasis Free Survival
Will be summarized using the Kaplan-Meier method according to treatment group.
Time frame: Up to 5 years